共 201 条
[1]
Barnet MB(2018)Immunotherapy in non-small cell lung cancer: shifting prognostic paradigms J Clin Med 9 12452-12470
[2]
Cooper WA(2018)Current status and perspectives in immunotherapy for metastatic melanoma Oncotarget 63 122-134
[3]
Boyer MJ(2018)Checkpoint inhibitors in breast cancer—current status Cancer Treat Rev 122 202-207
[4]
Marconcini R(2018)Immunotherapy, an evolving approach for the management of triple negative breast cancer: converting non-responders to responders Crit Rev Oncol Hematol 24 2804-2811
[5]
Spagnolo F(2018)Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer Clin Cancer Res 406 747-752
[6]
Stucci LS(2000)Molecular portraits of human breast tumours Nature 26 1488-1493
[7]
Polk A(2015)PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes Ann Oncol 162 19-30
[8]
Svane I-M(2017)PD-L1 expression and tumor infiltrating PD-1 + lymphocytes associated with outcome in HER2 + breast cancer patients Breast Cancer Res Treat 121 751-758
[9]
Andersson M(2017)Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients Int J Mol Sci 8 31347-31354
[10]
Tolba MF(2007)Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells Int J Cancer 24 S26-S35